Radical nephroureterectomy is the standard operation for most high-risk, non-metastatic upper tract urothelial cancers. It removes the affected kidney, the entire ureter and a cuff of bladder around the ureteric opening. Removing the whole ureter and bladder cuff is important because leaving a distal ureteric segment can allow urothelial cancer to recur there. The operation may be open, laparoscopic or robotic. Lymph-node dissection may be added according to tumour location and stage. Because one kidney is removed, kidney function and possible need for peri-operative chemotherapy should be considered before surgery.

Who usually needs nephroureterectomy?

High-grade biopsy/cytology, invasive disease on imaging, large or multifocal tumours, high-risk histological features or disease not suitable for reliable endoscopic control commonly favour radical surgery. Selected low-risk tumours may instead be managed with kidney-sparing endoscopic treatment or segmental ureterectomy.

What is removed?

• Affected kidney
• Entire ureter
• Bladder cuff surrounding the ureteric orifice
• Regional lymph nodes when indicated by risk/stage and surgical plan

How is the operation performed?

The kidney portion is commonly approached laparoscopically or robotically in suitable patients, with careful handling to avoid tumour spillage. The distal ureter and bladder cuff must be excised completely. Open surgery remains appropriate for bulky, invasive or technically complex disease.

Chemotherapy and timing

Kidney function often falls after nephroureterectomy, which can make cisplatin chemotherapy harder to deliver. For selected high-risk patients, neoadjuvant chemotherapy before surgery may therefore be discussed. Adjuvant platinum-based chemotherapy can also be considered based on final pathology and renal function.

Risks and recovery

• Bleeding, infection and blood clots
• Injury to surrounding bowel or major vessels
• Urine leak from bladder repair
• Reduced kidney function
• Wound or hernia problems
• Bladder recurrence or metastatic recurrence despite surgery

Follow-up after surgery

Surveillance includes cystoscopy because bladder recurrence is common, plus imaging of the remaining upper tract/chest/abdomen according to risk. Kidney function is monitored and systemic treatment may be recommended if final pathology shows high-risk disease.

Why the bladder cuff is oncologically important

The ureter passes through the bladder wall before opening into the bladder. Urothelial cancer can recur in any retained distal ureter, so radical nephroureterectomy includes removal of this intramural segment and a cuff of bladder around the ureteric orifice. The operation is more than nephrectomy plus cutting the ureter high.

Chemotherapy should be discussed before kidney function is lost

Cisplatin eligibility often depends on renal function. Because eGFR can fall after removal of one kidney, a patient with convincing high-risk non-metastatic UTUC may be evaluated for neoadjuvant cisplatin-based chemotherapy before surgery. Adjuvant platinum chemotherapy remains relevant based on final pathology and postoperative renal function.

Bladder recurrence is not evidence that the kidney operation “failed”

A later bladder tumour can arise because the entire urothelial lining is biologically at risk. This is why cystoscopy continues after nephroureterectomy. Selected patients may also receive a postoperative intravesical chemotherapy instillation to reduce bladder recurrence risk when appropriate.

The bladder cuff is part of the cancer operation

Nephroureterectomy for high-risk UTUC is not simply nephrectomy plus an incidental ureter removal. The entire ureter, including its intramural segment and bladder cuff, must be managed appropriately because leaving distal ureter behind increases recurrence risk. Kidney function before surgery also matters: loss of renal reserve can affect future eligibility for cisplatin-based chemotherapy, which is one reason peri-operative systemic treatment is discussed before the kidney is removed in selected patients.

When to seek earlier medical review

After nephroureterectomy, report fever, increasing abdominal/flank pain, persistent vomiting, wound drainage, reduced urine output or breathlessness. Once pathology is available, arrange timely review because pT2–T4 or node-positive disease can raise a time-sensitive discussion about adjuvant therapy.

What to bring to your consultation

• CT urography and staging images
• Ureteroscopy/biopsy/cytology
• Creatinine/eGFR
• Previous bladder-cancer and chemotherapy records

Questions to ask your doctor

• Is neoadjuvant cisplatin worth discussing before renal function falls?
• Will the entire intramural ureter and bladder cuff be removed?
• What bladder-surveillance schedule will I need afterward?

FAQs

Related reading

• Upper Tract Urothelial Cancer Explained
• Ureter Cancer Explained
• Renal Pelvis Cancer Explained
• CT Urography for Upper Tract Cancer
• Urologist in Latur

References

• European Association of Urology (EAU). Upper Urinary Tract Urothelial Cell Carcinoma Guidelines. Diagnosis https://uroweb.org/guidelines/upper-urinary-tract-urothelial-cell-carcinoma/chapter/diagnosis
• European Association of Urology (EAU). Upper Urinary Tract Urothelial Cell Carcinoma Guidelines. Disease Management https://uroweb.org/guidelines/upper-urinary-tract-urothelial-cell-carcinoma/chapter/disease-management
• National Cancer Institute. Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ) https://www.cancer.gov/types/kidney/hp/transitional-cell-treatment-pdq